Cardiovascular effect of imipramine and nortriptyline in elderly patients. 1981

P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram

Cardiovascular effects in elderly depressed patients (age 62-78 years) treated with imipramine (N = 11) or nortriptyline (N = 10) were recorded by monitoring of heart rate, blood pressure, systolic time intervals, standard ECG and 24-h ECG. The two drugs exhibited distinctly different cardiovascular reactions. The use of imipramine was severely limited by orthostatic hypotension occurring at subtherapeutic plasma levels, which resulted in falls with fracture in two patients. In contrast, nortriptyline at therapeutic drug levels did not significantly influence orthostatic blood pressure regulation. Nortriptyline caused moderate changes in systolic time intervals, indicating impairment in myocardial contractility. This effect was not seen with imipramine, but a majority of the patients did not reach therapeutic plasma levels because of blood pressure reactions. Neither imipramine nor nortriptyline induced changes in cardiac conduction time measurements or arrhythmias. In addition to the blood pressure reactions, the use of imipramine was complicated by dose dependent kinetics.

UI MeSH Term Description Entries
D007099 Imipramine The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. Imidobenzyle,Imizin,4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2),Imipramine Hydrochloride,Imipramine Monohydrochloride,Imipramine Pamoate,Janimine,Melipramine,Norchlorimipramine,Pryleugan,Tofranil
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009661 Nortriptyline A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions. Desitriptyline,Desmethylamitriptylin,Allegron,Apo-Nortriptyline,Aventyl,Gen-Nortriptyline,Norfenazin,Nortrilen,Nortriptyline Hydrochloride,Novo-Nortriptyline,Nu-Nortriptyline,PMS-Nortriptyline,Pamelor,Paxtibi,ratio-Nortriptyline,Apo Nortriptyline,Gen Nortriptyline,Hydrochloride, Nortriptyline,Novo Nortriptyline,Nu Nortriptyline,PMS Nortriptyline,ratio Nortriptyline
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
February 1984, Clinical pharmacology and therapeutics,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
November 1966, Danish medical bulletin,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
January 1970, The American journal of psychiatry,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
October 2002, Journal of clinical psychopharmacology,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
May 1992, Progress in neuro-psychopharmacology & biological psychiatry,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
February 1990, The Journal of clinical psychiatry,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
May 1985, American heart journal,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
February 1995, Nihon rinsho. Japanese journal of clinical medicine,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
August 1980, The American journal of psychiatry,
P Thayssen, and M Bjerre, and P Kragh-Sørensen, and M Møller, and O L Petersen, and C B Kristensen, and L F Gram
May 1987, Pain,
Copied contents to your clipboard!